Astria Therapeutics presents new Phase 1a data confirming potential for STAR-0125 at the 2023 American College Of Allergy, Asthma, And Immunology Annual Meeting
Astra Therapeutics presented new STAR-0215 data at the American College of Allergy, Asthma, and Immunology (ACAAI) Meeting, that demonstrated STAR-0215’s profile as a potential HAE preventative therapy with robust attack suppression and low treatment burden in healthy adult subjects. These data confirm the potential for STAR-0215 to be dosed once every three months and every six months.
Chris Morabito, M.D., Chief Medical Officer at Astria, said: “These new data, including long-term follow-up from the original cohorts and initial data from new, higher dose cohorts, support our vision for STAR-0215 as a first-choice therapy for HAE. These data confirm our approach to administer STAR-0215 once every three and every six months in future trials. We intend to provide patients the option to choose what works best for their lives with a therapy that has a trusted modality and mechanism.
“Our Phase 1b/2 ALPHA-STAR trial in HAE patients is on track and enrolling the third and final cohort. We now expect to deliver initial proof-of-concept data for STAR-0215 as a long-acting preventative therapy for HAE in Q1 2024. Patients from the ALPHA-STAR trial are enrolling in the long-term open label ALPHA-SOLAR trial to continue receiving STAR-0215, with data now accruing in patients who have received multiple doses of STAR-0215.”
(Source: Astria)
